Strategies of targeting glutaminase (which generates glutamate from glutamine) or glutaminolysis pathway proteins are developed to suppress tumor growth in leukemia, liver and pancreatic cancers, all of which showed therapeutical efficacy at least in preclinical studies (50–55). This evidence concerns the gene GLS and leukemia.